Rapid Autopsy program

• Sample of RA consent form 

• NCI will cover all costs associated with the study, transporting of the body, as well as the cremation and an urn. They will provide the family with a letter of appreciation for the donation.

• NCI will also cover the cost of 3 copies of the death certificate 

• Religious considerations can be shared with the team during the admissions process

Information Needed for Admissions: 

Demographic details:

• Full Name

• Date of Birth

• Current Address and Contact Number

• Dual Power of Attorney documents for patient’s post-mortem legal representative 

Medical records: To be forwarded from the medical facility of the patient. 

• Demographic Sheet

• Recent Comprehensive Progress Note

• All Pathology Reports (including molecular profiling)

• Wax/Paraffin Tissue Block with one H&E stained slide from case OR
  • 15-20 unstained slides with one H&E stained slide

• Latest Laboratory Results

• Scans and Reports of all Radiology Scans

• Operative Notes or Radiation Summaries (if applicable)

• Once information is received, NCI will conduct their own pathology on the tissue provided

• Following the completion of the pathology, patient and/or legal representative will sign the RA consent form

• Admissions will follow up with patient and/or legal representative to complete and sign necessary admissions forms electronically 

Post-mortem Process:

• At the time of death, call the admissions main phone number - 301-496-3141

• Admissions will email or fax 3 documents for legal representative to be signed and sent back immediately:

• Authorization for Release of Human Remains

• Authorization for Autopsy

• Next of Kin’s Instructions Regarding Disposition of Body

• NCI appointed funeral home will then collect the body and take it to NIH for the autopsy

• RA program representatives will keep in contact to provide updates on findings of the autopsy. 

• Following the autopsy, the body will be cremated, and cremains will be sent back to the family. 

PAPILLON: Adding Amivantamab to First-Line Chemotherapy Prolongs Progression-Free Survival in NSCLC Subset
By The ASCO Post Staff
December 10, 2023 - Supplement: ESMO Highlights

National Lung Screening Trial Results Highlight Importance of Lifelong Follow-up
By The ASCO Post Staff
October 10, 2022 - Supplement: Conference Highlights IASLC 2022

Screening for Lung Cancer with Low Dose Computed Tomography (LDCT)—CMS.gov Centers for Medicare & Medicaid Services

INHERIT EGFR - Studying Germline EGFR Mutations (INHERIT) —ClinicalTrials.gov

EGFR Exon 20 Insertion Mutation and Lung Cancer—American Lung Association

---